Prevention of acute and delayed chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline
Priya Patel, Paula D. Robinson, Marie Cohen, Katie A. Devine, Paul Gibson, Mark T. Holdsworth, Eloise Neumann, Andrea D. Orsey, Robert Phillips, Daniela Spinelli, Jennifer Thackray, Marianne D. van de Wetering, Deborah Woods, Sandra Cabral, Lillian Sung, L. Lee Dupuis
Abstract
This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.